New hope for advanced cancer? early trial of CMAB017 begins
NCT ID NCT06933069
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This early-phase study tests a new drug called CMAB017 in about 55 people with advanced solid tumors (like head and neck, colorectal, or esophageal cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must be 18-75 and have no other standard options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.